Ownership and insider activity for NanoVibronix, Inc. (NAOV): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
NanoVibronix, Inc., operating through its subsidiary NanoVibronix Ltd., develops and commercializes innovative, non-invasive devices that stimulate biological responses for therapeutic purposes. Their core focus areas include mitigating biofilm formation, accelerating wound repair, and alleviating pain.
Price
| Price | $1.90 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $106000 | $4.4M | $896000 | $1.3M | $7.1M | $7.7M | $2.7M | $3.3M | $752000 | $4.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $14000 | $35000 | $144000 | $130000 | $93000 | $200000 | $109000 | $425000 | $268000 | $391000 |
| Inventory | $67000 | $76000 | $144000 | $121000 | $145000 | $175000 | $2.2M | $2.7M | $2.2M | $2.3M |
| Total Current Assets | $221000 | $4.5M | $1.2M | $1.8M | $8.0M | $8.3M | $5.6M | $6.5M | $3.3M | $7.3M |
| Property, Plant & Equipment | $11000 | $6000 | $8000 | $4000 | $35000 | $54000 | $88000 | $12000 | $125000 | $246000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $29.1M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $4.4M |
| Total Assets | $494000 | $4.9M | $1.6M | $2.0M | $8.2M | $8.6M | $5.9M | $6.7M | $3.6M | $41.1M |
| Accounts Payable | $82000 | $168000 | $193000 | $129000 | $144000 | $87000 | $66000 | $138000 | $47000 | 0 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $89000 |
| Total Current Liabilities | $565000 | $797000 | $640000 | $409000 | $2.9M | $1.9M | $2.3M | $2.5M | $2.7M | $6.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $28000 |
| Total Liabilities | $3.0M | $1.2M | $1.1M | $688000 | $5.8M | $2.3M | $2.6M | $2.7M | $3.0M | $7.6M |
| Retained Earnings | -$22.6M | -$28.4M | -$32.5M | -$38.3M | -$42.7M | -$56.9M | -$62.4M | -$66.1M | -$69.8M | -$90.5M |
| Total Equity | -$2.5M | $3.6M | $463000 | $1.3M | $2.4M | $6.3M | $3.2M | $4.0M | $627000 | $33.5M |
| Total Debt | 0 | 0 | 0 | 0 | $31000 | $49000 | $81000 | $5000 | $116000 | $117000 |
| Net Debt | -$106000 | -$4.4M | -$896000 | -$1.3M | -$7.1M | -$7.7M | -$2.6M | -$3.3M | -$636000 | -$4.1M |
| Working Capital | -$344000 | $3.7M | $586000 | $1.4M | $5.1M | $6.4M | $3.3M | $4.0M | $609000 | $611000 |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 0.66 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -4.72 |
Profitability
| Return on Equity | -54.29% |
| Return on Invested Capital | -65.14% |
| Return on Assets | -44.22% |
| Gross Margin | -26.06% |
| Operating Margin | -1362.72% |
| Net Margin | -1259.55% |
Related companies: ACON · AMIX · BBLG · BJDX · CNSP · GRI · HSCS
Explore sector: Healthcare · Medical - Devices
More sections of NAOV: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks